載入...
A novel anti-melanoma SRC-family kinase inhibitor
The major drawback of melanoma therapy with BRAF and MAPK inhibitors is the innate and acquired drug resistance. We therefore explored alternative targets and developed a new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor. The drug is cytotoxic to patient-derived melanoma cells regard...
Na minha lista:
| 發表在: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Impact Journals LLC
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6481345/ https://ncbi.nlm.nih.gov/pubmed/31040916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26787 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|